GRA President and CEO Susan Shows to Retire with 22-Year Legacy

Tenure marked by shaping all major aspects of the organization

Susan Shows headshot

A driving factor in the development and success of the Georgia Research Alliance over a tenure that has spanned more than two decades, President and CEO Susan Shows today announced her retirement from the Alliance at the fall meeting of GRA’s Board of Trustees.

Since joining GRA in 2001 as vice president, Shows was instrumental in shaping each of the organization’s areas of operation. She worked closely with member universities to bring top scientific talent to their campuses, playing an active role in the recruitment of most of GRA’s 78-member Academy of Scientists. She also partnered with university leaders to identify “best investments” in high-tech lab equipment and core research facilities to make Georgia’s institutions more competitive in winning lucrative research grants and contracts.

And 20 years ago, she served as chief architect of GRA’s venture development program, a multi-faceted enterprise that has helped launch 240 high-potential startup companies with operations in Georgia, all based on inventions made by university scientists in Georgia.

While serving in the senior vice president role, Shows placed collaboration and impact at the center of these and other activities. She often brokered working partnerships among scientists and universities and between academia and industry. And she developed the statistical framework for providing funders with an accountability of GRA’s performance and its return on the state’s investment in GRA programs.

Since being named president and CEO of GRA in September 2020, Shows has continued to grow GRA’s talent, infrastructure and entrepreneurship programs while also launching several initiatives that leverage university research strengths to address areas of priority for the state.  

“GRA owes so much of its success to Susan, and it would not be the organization it is today without her,” says GRA Board Chair David Ratcliffe. “Her early work in GRA’s program areas was both foundational and durable. As president and CEO, she has brought a new level of agility to the Alliance by creating and seizing opportunities to make an impact in agricultural technology, artificial intelligence, Sickle Cell Disease and workforce development.  And the taxpayers of Georgia should be pleased to know that GRA’s return on investment grew to $13 billion this year.”

Shows will continue to serve in an advisory role until the end of GRA’s fiscal year next June. In reflecting on her tenure with the Alliance, Shows said: “GRA works in so many different ways for the single purpose of growing Georgia’s economy. It has been a great privilege to have been a part of this unique organization, and to have worked on teams of true professionals in government, industry and academia, all to benefit Georgia’s excellent universities and the state as a whole.”

Georgia’s Life Sciences Momentum is Getting Noticed Nationally.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS